Pfizer has opened a new, $214 million biotech manufacturing facility in Sweden. The 68,000-square-foot plant will make recombinant proteins based on e. coli and yeast as well as a branded human growth hormone. But Pfizer says that it built the plant to accommodate the production of a variety of therapies. Report